Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Durect, a specialty pharmaceutical company, has announced that Takeda intends to return its development and commercialization rights to Posidur (Saber Bupivacaine) in Europe and their other licensed territories.
Subscribe to our email newsletter
Posidur is a post-operative pain relief depot that utilizes Durect’s patented Saber technology to deliver bupivacaine and is designed to provide up to three days of pain relief after surgery.
Takeda acquired its rights to POSIDUR through its acquisition of Nycomed in September 2011.
Posidur is licensed to Hospira for commercialization in the US and Canada.
Durect retains commercialization rights for the product in the rest of the world.